Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

Comprehensive description: This is a brightfield, Wright-Giemsa stained peripheral blood smear examined by light microscopy at high magnification (oil immersion). The specimen shows several activated (atypical) lymphocytes in the peripheral blood, a hallmark of infectious mononucleosis. The lymphocytes have abundant basophilic cytoplasm and irregular, often indented nuclei with clumped chromatin and inconspicuous nucleoli. A normal segmented neutrophil is present for contrast. Erythrocytes exhibit occasional cytoplasmic membrane scalloping around red cells, a feature sometimes observed in EBV-related lymphocytosis. The background cytology is otherwise typical, with uniform erythrocytes and occasional platelets. The activated lymphocytes vary in size and cytoplasmic texture, some appearing plasmacytoid with vesicular basophilia, while others are more indented with coarse chromatin. These morphologic changes reflect an immune response to Epstein-Barr virus infection and are described as reactive lymphocytosis. Clinically, the combination of acute lymphadenitis, fever, a positive Monospot test, and EBV serology supports infectious mononucleosis. The image helps differentiate viral-induced lymphocytosis from bacterial lymphadenitis and from hematologic malignancies when integrated with clinical data. In summary, this smear illustrates the classical hematologic manifestation of EBV-associated mononucleosis. These atypical lymphocytes, sometimes named Downey cells, accompany fever and pharyngitis in EBV infection and aid differentiation from leukemia when combined with serology and clinical data.

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

Bone marrow aspirate smear analyzed by light microscopy with high magnification reveals marrow involvement by chronic lymphocytic leukemia (CLL) cells. The predominant population consists of small, dark lymphocytes with scant cytoplasm and condensed, clumped nuclear chromatin, producing high nuclear-to-cytoplasmic ratios. Occasional larger forms and prolymphocytes may be present but are uncommon. A consistent finding is the relative scarcity of cytoplasm and uniform round to slightly irregular nuclei among the bulk of lymphoid cells. The smear may show scattered megakaryocytes, reflecting concurrent hematopoietic activity within the aspirate. Morphology mirrors circulating leukemic cells, consistent with systemic disease. Clinically, such marrow infiltration is associated with cytopenias and advanced disease stage, especially when diffuse, solid infiltration predominates in core biopsy patterns; these patterns correlate with adverse prognosis and with expression of prognostic markers such as ZAP-70. The image corresponds to a high-magnification field intended to document cellular detail rather than architectural marrow patterns. Diagnostic significance lies in confirming lymphoid marrow involvement by CLL, quantifying blast equivalents is not applicable, and differentiating from other small B-cell neoplasms relies on adjunct flow cytometry, cytogenetics, and immunophenotyping. This representation is typical for educational, diagnostic, and research contexts describing CLL marrow morphology.

This histopathology image depicts bone marrow involvement by undifferentiated neuroblastoma. Obtained from a bone marrow biopsy and stained with hematoxylin and eosin, bright-field microscopy at high magnification (approximately 400x). The cellular pattern shows densely packed small round blue neuroblasts with high nuclear-to-cytoplasmic ratio, finely textured hyperchromatic nuclei, inconspicuous nucleoli, and scant cytoplasm. Cells are arranged in diffuse sheets with minimal intervening stroma; occasional Homer Wright–type rosettes may be present, reflecting neural differentiation. Mitotic activity is variable and cytologic features are consistent with embryonal neuroblastic morphology. The marrow is variably replaced by tumor cells, producing a high cellular density and occasional recrudescence of residual hematopoiesis at the periphery. Immunohistochemistry, when performed, typically demonstrates positivity for neuronal markers such as synaptophysin, chromogranin A, and neurofilament protein, supporting neuroblastic lineage; NB84 positivity may be observed in selected cases. Clinically, bone marrow involvement correlates with advanced disease and elevated catecholamines (serum VMA/HVA) in many patients. This image exemplifies a high-grade, poorly differentiated neuroblastoma phenotype, which carries prognostic and therapeutic implications, including risk-stratified chemotherapy, surgical planning, and monitoring for residual disease during follow-up. Recognition of perivascular tumor clusters and subtle stromal response can further refine staging and influence multidisciplinary management decisions in pediatric oncology practice.

High-magnification brightfield micrograph of a human bone marrow aspirate smear stained with Hematoxylin and Eosin, demonstrating dysplastic megakaryocytes in a hematopoietic background. The megakaryocytes exhibit atypical nuclear morphology, including multinucleation, irregular lobulation, and nuclear fragmentation, with variable cytoplasmic basophilia. Background cellularity shows concurrent dyserythropoiesis and dysplastic myeloid precursors consistent with a myelodysplastic spectrum. Overall architecture may be hypercellular or variably cellular, with scattered normal hematopoietic elements interspersed among abnormal cells. Features are most prominent in the megakaryocytic lineage, where dysplasia is a salient hallmark. The image illustrates morphologic criteria that support a diagnosis in the context of possible progression toward acute leukemia, and should be correlated with peripheral blood counts, marrow blast percentage, cytogenetic and molecular studies. Clinically, such dysplastic megakaryocytes are associated with cytopenias and splenomegaly, and approximately a fifth of patients with related myelodysplastic/myeloproliferative conditions progress to acute myeloid leukemia. This representation is valuable for educational, diagnostic, and research purposes, particularly in studies of megakaryocytic dysplasia, MDS/AML continuum, prognostication, and therapeutic planning focused on palliation and cytopenia management. Careful documentation of features and context enhances reproducibility, supports standardized reporting, and facilitates cross-institutional data sharing for outcome studies and biomarker-driven clinical trials.